
The episode discusses significant ASH abstracts in leukemia with insights from Dr. Justin Kaner.
In this episode, Anthony and Bernie are joined by special guest, Dr. Justin Kaner from Weill Cornell Medicine, to discuss some of the most interesting ASH abstracts in leukemia in 2025! What abstracts should change practice? Listen to find out. Some of the abstracts discussed: PARADIGM: https://meetings-api.hematology.org/api/abstract/vmpreview/296881 KMT2A Outcomes (MARROW Consortium and Othman, et al.): https://meetings-api.hematology.org/api/abstract/vmpreview/302582 and https://meetings-api.hematology.org/api/abstract/vmpreview/297333 CLIA +/- Ven: https://meetings-api.hematology.org/api/abstract/vmpreview/302047 FLT3i studies (and MRD): https://meetings-api.hematology.org/api/abstract/vmpreview/295719 and https://meetings-api.hematology.org/api/abstract/vmpreview/302699 and https://meetings-api.hematology.org/api/abstract/vmpreview/291322 ALL GIMEMA Trial (blin + ponatinib): https://meetings-api.hematology.org/api/abstract/vmpreview/296532 Menin inhibitor data
Hosts: Anthony Perissinotti, Bernard Marini
Guest: Dr. Justin Kaner
Organizations: Weill Cornell Medicine
Books & works: PARADIGM, KMT2A Outcomes, CLIA +/- Ven, FLT3i studies, ALL GIMEMA Trial, Menin inhibitor data
Explore listener stats, chart rankings, contacts and more on the WolverHeme Happy Hour podcast page.